Cost-Effectiveness Model of Use of Genetic Testing as an Aid in Assessing the Likely Benefit of Aspirin Therapy for Primary Prevention of Cardiovascular Disease

LPA genotyping in the context of the aspirin use guidelines for primary prevention of CVD could be cost-effective.